Similarly, recent studies in a genetically engineered mouse model of colorectal carcinoma demonstrated increased expression of PD-1 and Granzyme B on tumor-infiltrating CD8+ T cells following galunisertib (a small-molecule selective inhibitor of TGF-β receptor type I) administration, which was further enhanced in combination with anti-PD-L17. The gene discussed is CD8A; the disease is neoplasm.